In late 2025, Arcturus Therapeutics Holdings Inc. filed an omnibus shelf registration of up to US$500 million, covering common and preferred stock, debt securities, warrants, rights, and units. This ...

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings. The information provided on PharmiWeb.com is ...

SAN DIEGO, January 08, 2026--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

An update from Arcturus Therapeutics ( (ARCT)) is now available. On December 11, 2025, Arcturus Therapeutics announced the amicable departure of its Chief Financial Officer, Andy Sassine, effective ...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) stock was trading lower on Wednesday after the company shared interim results from its ongoing Phase 2 trial of ARCT-032, an investigational inhaled ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...

Arcturus Therapeutics sued AbbVie and Capstan Therapeutics for allegedly misusing its lipid nanoparticle (LNP) delivery technology after former staff joined Capstan. The case spotlights the high ...

AbbVie, Capstan Therapeutics and other defendants were hit with a trade secret lawsuit on Sept. 23 in California Southern District Court. The suit, filed by Wilson Sonsini Goodrich & Rosati on behalf ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

Friday, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with cystic fibrosis for ARCT-032, an inhaled ...